Search Results for "Ranbaxy Launches Atorvastatin In Us"

15:55 EST 23rd November 2014 | BioPortfolio

Matching Channels

Lipitor

Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is pres...

Matching News

U.S. Pay-To-Delay Suit Against Ranbaxy, Pfizer Rejected

A U.S. judge threw out a suit filed against Ranbaxy Laboratories and Pfizer alleging they colluded to delay the market introduction of a generic of the top-selling Lipitor (atorvastatin) for high chol...

Cipher Pharmaceuticals signs distribution agreement with Ranbaxy

MISSISSAUGA, ON- Cipher Pharmaceuticals Inc. announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Ltd., granting Ranbaxy exclusive rights to market, sell and dis...

Ranbaxy’s Valsartan ANDA Wins FDA Approval After Lengthy Delay

Regulatory nod gives Ranbaxy green light to launch its generic version of Novartis’ Diovan with 180-day exclusivity; other ANDA holders may continue to challenge Ranbaxy’s hold on the market.

U.S. FDA Slams Ranbaxy’s Claims In Nexium, Valcyte Lawsuit

The federal drug regulatory agency highlighted Ranbaxy’s faulty manufacturing practices, strongly retaliating to Ranbaxy’s claims in a lawsuit challenging its decision to rescind tentative approva...

FDA revokes tentative approval of Ranbaxy’s generic Nexium and Valcyte

Indian generics drugmaker Ranbaxy Laboratories revealed in a Bombay Stock Exchange filing that it has received communication from the US Food and Drug Administration, in which the agency said it has d...

Ranbaxy’s manufacturing woes benefit big pharma

Import bans by the US Food and Drug Administration (FDA) on generics from four of Ranbaxy Laboratories’ (Ranbaxy) manufacturing sites have prevented the company from launching new generics, allowing...

Ranbaxy’s Nexium Generic Exclusivity: A Hit Or A Miss?

The FDA has blocked Ranbaxy’s exclusivity on Roche’s antiviral drug valganciclovir, but has kept its options open on Nexium, the popular heartburn drug. Experts believe Ranbaxy’s Nexium launch o...

Sunshine finally: Ranbaxy gets FDA ok for Diovan generic

Finally, the sun seems to be shining on Ranbaxy. Ending prolonged speculation on the fate of its generic version of Novartis's blockbuster blood pressure treatment Diovan (valsartan) amid mounting pre...

Matching PubMed Articles

Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.

The objective of the present study was to develop bilayer tablets of atorvastatin and atenolol that are characterized by initial fast-release of atorvastatin in the stomach and comply with the release...

Efficacy and Safety of Alternate Day Therapy With Atorvastatin and Fenofibrate Combination in Mixed Dyslipidemia: A Randomized Controlled Trial.

Introduction:The long half-life of atorvastatin and fenofibrate makes them suitable for alternate day therapy. Hence, we aimed to study the efficacy, safety, and cost-effectiveness of alternate day th...

Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial.

Background. Treatment of hyperlipidemia is helpful in both primary and secondary prevention of coronary heart disease and stroke. Aim. To compare lipid-lowering efficacy of rosuvastatin with atorvasta...

The Effect of Atorvastatin and Atorvastatin-Ezetimibe Combination Therapy on Androgen Production in Hyperandrogenic Women with Elevated Cholesterol Levels.

Statins decreased serum androgen levels in hyperandrogenemic women with polycystic ovary syndrome. No previous study has investigated whether this effect is dose-dependent and observed in patients sim...

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) risk, if needed, after lifestyle changes...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement